Skip to content

Study · Animal study (in vivo) · rat · 2004

5 results

[Effect of ladasten on the proteinase C activity in the rat brain cells].

Vakhitova IuV, Salimgareeva MKh, Seredenin SB

Eksperimental'naia i klinicheskaia farmakologiia1 Mar 2004Cited by 1 (Europe PMC)

PMID15188752 (opens in a new tab)PepBankPUB-15188752
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rat brain, ladasten increased cytosolic PKC activity more than twofold during the initial drug-action stage.

    In plain wordsIn rats, ladasten more than doubled brain cytosolic PKC activity during its initial action.

    Peptide
    Bromantane
    Outcome
    IncreaseCytosolic PKC activity
    Study

    ratn: not reported in source

    Rat brain
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    50 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    In the initial stage of the drug action, the PKC activity in the cytosol fraction of rat brain proteins exhibits a more than twofold increase.
    1 context sentence
    Summary · context
    The effect of ladasten (50 mg/kg) on the activity of protein kinase C (PKC) in rat brain was studied depending on the duration of drug action.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rat brain, the ladasten-associated PKC effect did not depend on exogenous calcium.

    In plain wordsIn rats, the brain PKC effect associated with ladasten did not depend on added calcium.

    Peptide
    Bromantane
    Outcome
    Not applicableExogenous calcium dependence of PKC effect
    Study

    ratn: not reported in source

    Rat brain
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    50 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    The effect is independent of the presence of exogenous Ca2+ and is inhibited by cinnarizine and nifedipine.
    2 context sentences
    Summary · context
    In the initial stage of the drug action, the PKC activity in the cytosol fraction of rat brain proteins exhibits a more than twofold increase.
    Summary · context
    The effect of ladasten (50 mg/kg) on the activity of protein kinase C (PKC) in rat brain was studied depending on the duration of drug action.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rat brain studied after ladasten, calcium ATPase activation maintained the optimum calcium concentration.

    In plain wordsIn rats studied after ladasten, calcium ATPase activation maintained the optimum calcium concentration.

    Peptide
    Bromantane
    Outcome
    IncreaseCalcium ATPase activation
    Study

    ratn: not reported in source

    Rat brain
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    50 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    The optimum Ca2+ concentration is maintained due to the activation of Ca2+ ATPase.
    1 context sentence
    Summary · context
    The effect of ladasten (50 mg/kg) on the activity of protein kinase C (PKC) in rat brain was studied depending on the duration of drug action.

Studies that did not test the peptide alone2

In this study, Bromantane was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Bromantane.

  1. 04AnimalNot a test of Bromantane aloneAnimal study (in vivo)Mechanism

    In rat brain, cinnarizine inhibited the ladasten-associated PKC effect.

    In plain wordsIn rats, cinnarizine inhibited the brain PKC effect associated with ladasten.

    Peptide
    Bromantane
    Outcome
    DecreaseCinnarizine inhibition of PKC effect
    Study

    ratn: not reported in source

    Rat brain
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    The effect is independent of the presence of exogenous Ca2+ and is inhibited by cinnarizine and nifedipine.
    2 context sentences
    Summary · context
    In the initial stage of the drug action, the PKC activity in the cytosol fraction of rat brain proteins exhibits a more than twofold increase.
    Summary · context
    The effect of ladasten (50 mg/kg) on the activity of protein kinase C (PKC) in rat brain was studied depending on the duration of drug action.

    In this study, Bromantane was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bromantane.

  2. 05AnimalNot a test of Bromantane aloneAnimal study (in vivo)Mechanism

    In rat brain, nifedipine inhibited the ladasten-associated PKC effect.

    In plain wordsIn rats, nifedipine inhibited the brain PKC effect associated with ladasten.

    Peptide
    Bromantane
    Outcome
    DecreaseNifedipine inhibition of PKC effect
    Study

    ratn: not reported in source

    Rat brain
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    The effect is independent of the presence of exogenous Ca2+ and is inhibited by cinnarizine and nifedipine.
    2 context sentences
    Summary · context
    In the initial stage of the drug action, the PKC activity in the cytosol fraction of rat brain proteins exhibits a more than twofold increase.
    Summary · context
    The effect of ladasten (50 mg/kg) on the activity of protein kinase C (PKC) in rat brain was studied depending on the duration of drug action.

    In this study, Bromantane was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bromantane.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.